Mini-Reviews in Medicinal Chemistry, Vol 15, No 4 (2015)

Font Size:  Small  Medium  Large

Breast Cancer Proteases; A Challenging Prognostic Biomarkers And Therapeutic Targets

Dr. Ghadeer Abdul Rahman Suaifan, Ms. Deema Jaber, Dr. Mayadah Shehadeh, Prof. Mohammed Zourob


Breast cancer is the second leading cause of cancer-related death among women in the Western World. Upon diagnosis and treatment in the preinvasive state, the five years survival rate levitate up to 93 %, making early detection crucial for dedicative diagnosis and treatment. Currently, mammography is the most efficacious diagnostic modality. However, this technique does not match the ultimate sensitivity. Other routinely used biomarkers include tumor size, histological type; nuclear and cellular characteristics, mitotic index, vascular invasion, hormonal and axillary lymph node status were frequently used. However, these biomarkers are not good enough to predict the course of this disease. Recent advances in molecular biology revealed innovative proteases biomarkers for early detection of breast cancer in patient`s tissue, serum and urine. Among which, kallikreins (KLK) and zinc metalloproteinases (such as Matrix Metalloproteinase (MMP) and A Disintegrin And Metalloproteinase (ADAM)) were pioneering prognostic biomarkers and therapeutic targets in breast cancer.


  • There are currently no refbacks.